➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Moodys
Baxter
McKesson
Medtronic

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for PF-06273340

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug PF-06273340?

PF-06273340 is an investigational drug.

There have been 4 clinical trials for PF-06273340. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2012.

The most common disease condition in clinical trials is [disabled in preview]. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There is one US patent protecting this investigational drug and thirty-two international patents.

Recent Clinical Trials for PF-06273340
TitleSponsorPhase
Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain EndpointsPfizerPhase 1
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)PfizerPhase 1
A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed StatePfizerPhase 1

See all PF-06273340 clinical trials

Clinical Trial Summary for PF-06273340

Top disease conditions for PF-06273340
Top clinical trial sponsors for PF-06273340

See all PF-06273340 clinical trials

International Patents for PF-06273340

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06273340 Argentina 085852 2031-04-05   Start Trial
PF-06273340 Australia 2012238369 2031-04-05   Start Trial
PF-06273340 Brazil 112013025792 2031-04-05   Start Trial
PF-06273340 Canada 2832291 2031-04-05   Start Trial
PF-06273340 Chile 2013002821 2031-04-05   Start Trial
PF-06273340 China 103534257 2031-04-05   Start Trial
PF-06273340 Colombia 6801740 2031-04-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Moodys
Baxter
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.